Adient (ADNT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Adient (ADNT) reported $3.61 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.7%. EPS of $0.69 for the same period compares to $0.54 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $3.47 billion, representing a surprise of +4.07%. The company delivered an EPS surprise of +91.67%, with the consensus EPS estimate being $0.36.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Adient performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales- Americas: $1.70 billion versus $1.59 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +2.4% change. Net Sales- Eliminations: -$26 million versus the two-analyst average estimate of -$21.46 million. The reported number represents a year-over-year change of +18.2%. Net Sales- Asia: $707 million versus the two-analyst average estimate of $735.50 million. The reported number represents a year-over-year change of -4.7%. Net Sales- EMEA: $1.23 billion compared to the $1.16 billion average estimate based on two analysts. The reported number represents a change of -10.2% year over year. View all Key Company Metrics for Adient here>>>Shares of Adient have returned +22.2% over the past month versus the Zacks S&P 500 composite's +10.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Adient (ADNT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks